Spondylarthritis
28
6
7
10
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.6%
1 terminated out of 28 trials
90.9%
+4.4% vs benchmark
4%
1 trials in Phase 3/4
0%
0 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (28)
Study of the Association Between Sacroiliitis/Axial Spondylarthritis and Giant Cell Arteritis/ Polymyalgia Rheumatica
EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
Effects of a Digital Exercise Intervention on Sleep and Physical Activity in Patients With Spondyloarthritis
Spondylo-arthritis Screening Tool Among Patient Suffering From Inflammatory Bowel Disease
COVID-19 VaccinE Response in Rheumatology Patients
Core Stabilization Training in Juvenile Spondyloarthropathy
Observational Prospective Turkish Inception Cohort of Uveitis and Spondyloarthritis
Assessment of Cardiorespiratory Fitness in Spondylarthritis
Mid- or High-flex Rods Versus Low-flex Rods of SpineShape System IV for Treatment of Degenerative Lumbar Spine Diseases
axSEND: Exploring Immune and Microbiota Effects of a Partial Enteral Nutrition Diet in Axial Spondyloarthritis
Calprotectine in Spondyloarthritis
Follow-up of Person-centered Care of Young Adults With Rheumatic Disease
Towards Telemonitoring in Immune-Mediated Inflammatory Diseases: Implementation of a Mixed Attention Model (IMIDOC)
Clinical Trial of Electroacupuncture in Axial Spondyloarthritis (E-AcuSpA)
Assessment of Whole Body Cryotherapy in Treatment of Active Axial Spondylarthritis
IL17 Rate and Spondyloarthritis
Multi-omics Study and Drug Intervention Study of Spondyloarthritis
Incidence of MRI Sacro-Iliac (SI) Joint Anomalies in Women With Spondyloarthritis (SpA)
A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation
Research Study on the Immunosuppressive Effects of a Cell Therapy Product on PBMC Isolated From Blood of Patients With Inflammatory Rheumatic Diseases